Welcome to our dedicated page for Hepion Pharmaceuticals SEC filings (Ticker: HEPA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how a clinical-stage biotech funds multi-phase liver trials and measures drug safety can feel like decoding a lab notebook. Hepion Pharmaceuticals’ disclosures mix capital-raise S-3s, trial-update 8-Ks, and an R&D-heavy 10-K in language only auditors enjoy. If you’ve ever typed “Hepion Pharmaceuticals quarterly earnings report 10-Q filing” or hunted for dilution math hidden in footnotes, you know the struggle. This page delivers Hepion Pharmaceuticals SEC filings explained simply, in one feed.
Stock Titan’s AI reads every paragraph so you don’t have to. Our platform turns dense tables into plain-English insights, highlighting cash runway, clinical milestone timing, and risk-factor changes in seconds. With understanding Hepion Pharmaceuticals SEC documents with AI, you’ll see real-time alerts the moment a Form 8-K material event is posted or a shelf registration drops. Drill straight into trial spend trends, patent status shifts, or going-concern language—without paging through hundreds of sections. Interactive dashboards surface segment disclosures, tax credits, and share-count movements, while side-by-side comparisons let you benchmark quarters quickly. You can even export the data to Excel for deeper modeling or set mobile alerts for any new clinical milestone.
For deeper dives, explore:
- Hepion Pharmaceuticals annual report 10-K simplified—spot year-over-year R&D and cyclophilin inhibitor progress.
- Hepion Pharmaceuticals insider trading Form 4 transactions plus Hepion Pharmaceuticals Form 4 insider transactions real-time to watch when executives trade around data readouts.
- Hepion Pharmaceuticals proxy statement executive compensation for details on option grants tied to trial success.
- Hepion Pharmaceuticals earnings report filing analysis that connects 10-Q numbers to pipeline catalysts.
- Hepion Pharmaceuticals 8-K material events explained so you can gauge trial announcements instantly.
Each section links to source PDFs and includes exportable tables for cash burn, share count, and Hepion Pharmaceuticals executive stock transactions Form 4 patterns. Make informed decisions faster—our AI summaries, real-time feeds, and complete coverage turn raw filings into actionable context.
Hepion Pharmaceuticals (HEPA) filed its Q3 2025 10‑Q, showing a continued business pivot from liver drug development to medical diagnostics. The company reported a Q3 net loss of $472,506 and a nine‑month net loss of $7,620,965. Operating expenses fell sharply as research and development dropped to zero for the quarter, while general and administrative expense was $527,902.
Cash was $2,321,078 at September 30, 2025, with total liabilities of $415,808 and stockholders’ equity of $3,324,432. Management states there is substantial doubt about the company’s ability to continue as a going concern without additional capital. Shares outstanding were 11,620,317 as of November 12, 2025.
Hepion in‑licensed diagnostic tests from New Day Diagnostics on May 9, 2025, paying $525,000 cash and $270,629 in stock, with up to $17.15 million in potential milestones; it recorded a $402,746 impairment. On May 26, 2025, it sold all rencofilstat assets to Panetta Partners for a nominal amount, with CVRs tied to future FDA approval and sales milestones. Earlier, the company raised approximately $9.0 million (January 23, 2025), repaid $2.9 million notes, effected a 1‑for‑50 reverse split, and transitioned trading to OTCQB after Nasdaq delisting.
Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA) filed a Form 8-K to disclose the resignation of Chief Financial Officer and director John Brancaccio. His departure, attributed to personal reasons, is effective June 30, 2025. The filing, made pursuant to Item 5.02, notes that Kaouthar Lbiati signs as Interim CFO. No additional management changes, compensation details, or financial data were provided.
FAQ
What is the current stock price of Hepion Pharmaceuticals (HEPA)?
What is the market cap of Hepion Pharmaceuticals (HEPA)?
